Clinical trial artificial intelligence company Antidote is looking to improve access to and enrollment in clinical trials using technology from the e-commerce world, according to a Wired report.
Former travel and airline fare aggregator Kayak VP Pablo Graiver is heading the operation, which streamlines access to clinical trials for patients seeking them out.
While open clinical trials are searchable through a government run national registry, navigating the trials can be extremely difficult, according to the report.
“Fundamentally, it’s a question of structuring information, which is something the tech world is great at. I was shocked no one had done it already,” Graiver said, according to the Wired report.
Antidote’s site allows patients to more easily search for possible clinical trials for their conditions, taking into account personal details for exclusion and inclusion that can often limit the size of studies, Wired said.
The site uses similar technology to travel fare aggregators like Orbitz or Kayak, and is entirely free for patients to use, outside of the cost of access to personal data, according to the report.
“It makes it less of a wild goose chase for patients. There’s just so much information for the common man or woman to get through. Technology can really make a patient’s journey easier,” Antidote partner PatientPower COO Esther Schorr said, according to Wired.
Antidote reportedly makes its money by selling limited access to the user database to pharmaceutical and clinical research institutions, though it claims that data is kept safe and that contact with patients on the site is limited to contact directly through the site.